TERATOGENIC EVALUATION OF A NEWLY SYNTHESIZED SULFONAMIDE COMPOUND

In this study, we investigated the effects of a newly synthesized sulfonamide compound, a pharmaceutical raw material (2a), which has been found to inhibit carbonic anhydrase I and II isoenzymes, on some developmental properties of Drosophila melanogaster. The administration of substance 2a to D. melanogaster was carried out by feeding, based on the value of Ki and using three different doses (2.12 mu l, 4.25 mu l and 8.50). The data were obtained from F-1 and F-2 generations. However, the substance was only applied to the parental individuals of the F-1 generation, which did not lead to a toxic effect in the F-1 generation but caused a decrease in the number of adult individuals and an increase in the number of abnormal individuals of the F-2 generation at the highest dose (8.50). The substance was only administered to parental individuals, which prevented direct contact of the F-2 generation with the substance. Therefore, the effects on the F-2 generation at the highest dose may be related to hereditary mutations. There was no deviation in the sex ratio in both generations, which can be interpreted as evidence of the absence of a sex-related effect of substance 2a. An unexpected result was the increase in the number of adult individuals in the positive control group (10 mM NaAsO2) of the F-2 generation. All these results are indicative that this new sulfonamide may be a promising therapeutic agent in the future.

Automated summary

The study investigated the effects of compound 2a on the developmental properties of Drosophila melanogaster. The results showed that the compound had a significant impact on the F-2 generation, with an increase in abnormal individuals at the highest dose. This new sulfonamide compound may be a promising therapeutic agent in the future.